Effect of tolcapone on the haemodynamic effects and tolerability of desipramine

European Neurology

Volumn 44, Issue 2, 2000, Pages 94-103

  Jorga, K M ^a   Fotteler, B ^a   Modi, M ^b   Rabbia, M ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

Catecholamines; Desipramine; Drug drug interactions; Haemodynamics; Tolcapone

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CATECHOLAMINE; DESIPRAMINE; PLACEBO; TOLCAPONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMODYNAMICS; HOT FLUSH; HUMAN; HYPERHIDROSIS; MALE; NORMAL HUMAN; PARKINSON DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TACHYCARDIA; VERTIGO;

EID: 0033803144     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000008204     Document Type: Article

References (21)

1. Baldessarini RJ: Inhibition of catechol-O-methyltransferase by L-dopa and decarboxylase inhibitors. J Pharm Pharmacol 1972;24: 78-79.
2. Baldessarini RJ, Greiner E: Inhibition of catechol-O-methyltransferase by catechols and polyphenols. Biochem Pharmacol 1973;22: 247-256.
3. Dingemanse J, Jorga K, Zurcher G, Schmitt M, Sedek G, Da Prada M, van Brummelen P: Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 1995;40:253-262.
4. Dingemanse J, Jorga K, Zurcher G, Fotteler B, Sedek G, Nielsen T, van Brummelen P: Multiple-dose clinical pharmacology of the catechol-O-methyltransferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol 1996;50: 47-55.
5. Jorga K, Fotteler B, Schmitt M, Nielsen T, Zurcher G, Aitken J: The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations. Eur Neurol 1997;38:59-67.
6. Jorga KM, Sedek G, Fotteler B, Zurcher G, Nielsen T, Aitken JW: Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly. Clin Pharmacol Ther 1997;62:300-310.
7. Waters CH, Kurth M, Bailey P, Shulman LM, LeWitt P, Dorflinger E, Deptula D, Pedder S, the Tolcapone Stable Study Group: Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment. Neurology 1997;49: 665-671.
8. Kurth MC, Adler CH, St Hilaire M, Singer C, Waters C, LeWitt P, Chernik DA, Dorflinger E, Yoo K, the Tolcapone Fluctuator Study Group I: Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: A multicenter, double-blind, randomized, placebo-controlled trial. Neurology 1997; 48:81-87.
9. Guldberg HC, Marsden CA: Catechol-O-methyl transferase: Pharmacological aspects and physiological role. Pharmacol Rev 1975;27: 135-206.
10. Mannisto PT: Clinical potential of catechol-O-methyltransferase (COMT) inhibitors as adjuvants in Parkinson's disease. CNS Drugs 1994; 1:172-179.
11. Rang HPP, Dale MM: Drugs used in affective disorders; in Rang HPP, Gardner P, Dale MM, Ritter JM (eds): Pharmacology, ed. 1. New York, Churchill Livingstone, 1995, pp 576-596.
12. Sutfin TA, De Vane CL, Jusko WJ: The analysis and disposition of imipramine and its active metabolites in man. Psychopharmacology 1984;82:310-317.
13. Nielsen KK, Brosen K: High-performance liquid chromatography of imipramine and six metabolites in human plasma and urine. J Chromatogr 1993;612:87-94.
14. Foglia JP, Sorisio D, Perel JM: Determination of imipramine, desipramine and their hydroxy metabolites by reversed-phase chromatography with ultraviolet and coulometric detection. J Chromatogr 1991;572:247-258.
15. Gibaldi M, Perrier D: Pharmacokinetics, ed 2. New York, Dekker, 1982.
16. van Kempen GMJ, Pearlman T, Karasu TB, Merriam AE, Glassman AH, Gelenberg AJ, Kupfer D: Practice guideline for adult major depressive disorder. Am J Psychiatry 1994; 151:625-626.
17. Chiu HF: Antidepressants in the elderly. Int J Clin Pract 1997;51:369-374.
18. Halper JP, Mann JJ: Cardiovascular effects of antidepressant medications. Br J Psychiatry Suppl 1988;3:87-89.
19. Goldman LS, Alexander RC, Luchins DJ: Monoamine oxidase inhibitors and tricyclic antidepressants: Comparison of their cardiovascular effects. J Clin Psychiatry 1986;47: 225-229.
20. Bock JL, Nelson JC, Gray S, Jatlow PI: Desipramine hydroxylation: Variability and effect of antipsychotic drugs. Clin Pharmacol Ther 1983;33:322-328.
21. Kutcher SP, Reid K, Dubbin JD, Shulman KI: Electrocardiogram changes and therapeutic desipramine and 2-hydroxy-desipramine concentrations in elderly depressives. Br J Psychiatry 1986;148:676-679.